Bio-Techne (TECH) 10-K 29 Aug 16 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Billions	12 Months Ended
	Jun. 30, 2016	Aug. 26, 2016	Dec. 31, 2015
Document Information [Line Items]
Entity Registrant Name	BIO-TECHNE Corp
Entity Central Index Key	842,023
Trading Symbol	tech
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Common Stock, Shares Outstanding (in shares)		37,296,323
Entity Public Float			$ 3.3
Document Type	10-K
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Statements of Earn

Consolidated Statements of Earnings and Comprehensive Income - USD ($) shares in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Net sales	$ 499,023,000	$ 452,246,000	$ 357,763,000
Cost of sales	162,364,000	144,969,000	106,352,000
Gross margin	336,659,000	307,277,000	251,411,000
Operating expenses:
Selling, general and administrative	140,879,000	119,401,000	60,716,000
Research and development	45,187,000	40,853,000	30,945,000
Total operating expenses	186,066,000	160,254,000	91,661,000
Operating income	150,593,000	147,023,000	159,750,000
Other income (expense):
Interest expense	(1,748,000)	(1,544,000)	0
Interest income	249,000	634,000	2,684,000
Other non-operating income (expense), net	(1,613,000)	8,049,000	(1,042,000)
Total other income (expense)	(3,112,000)	7,139,000	1,642,000
Earnings before income taxes	147,481,000	154,162,000	161,392,000
Income taxes	43,005,000	46,427,000	50,444,000
Net earnings	104,476,000	107,735,000	110,948,000
Other comprehensive income (loss):
Foreign currency translation adjustments	(19,932,000)	(36,513,000)	15,819,000
Unrealized (losses) gains on available-for-sale investments, net of tax of ($3,794), $3,895, and ($17,110) respectively	(19,924,000)	11,308,000	(35,760,000)
Other comprehensive (loss) income	(39,812,000)	(25,205,000)	(19,941,000)
Comprehensive income	$ 64,664,000	$ 82,530,000	$ 91,007,000
Earnings per share:
Basic (in dollars per share)	$ 2.81	$ 2.90	$ 3.01
Diluted (in dollars per share)	2.80	2.89	3
Cash dividends per common share: (in dollars per share)	$ 1.28	$ 1.27	$ 1.23
Weighted average common shares outstanding:
Basic (in shares)	37,194	37,096	36,890
Diluted (in shares)	37,326	37,231	37,005

Consolidated Statements of Ear3

Consolidated Statements of Earnings and Comprehensive Income (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Unrealized (losses) gains on available-for-sale investments, tax	$ (3,794)	$ 3,895	$ (17,110)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Current assets:
Cash and cash equivalents	$ 64,237,000	$ 54,532,000
Short-term available-for-sale investments	31,598,000	56,389,000
Accounts receivable, less allowance for doubtful accounts of $555 and $487, respectively	93,393,000	70,034,000
Deferred income taxes	0	11,511,000
Inventories	57,102,000	49,577,000
Other current assets	7,561,000	6,240,000
Total current assets	253,891,000	248,283,000
Property and equipment, net	132,362,000	129,749,000
Goodwill	430,882,000	390,638,000
Intangible assets, net	303,124,000	292,839,000
Other assets	1,922,000	1,851,000
	1,129,581,000	1,063,360,000
Current liabilities:
Trade accounts payable	20,653,000	13,443,000
Salaries, wages and related accruals	14,868,000	10,344,000
Accrued expenses	8,371,000	6,604,000
Deferred revenue	4,717,000	3,380,000
Income taxes payable	1,779,000	1,972,000
Related party note payable, current	3,759,000	4,024,000
Total current liabilities	54,147,000	39,768,000
Deferred income taxes	62,837,000	61,429,000
Long-term debt obligations	(91,500,000)	(73,000,000)
Contingent consideration payable	38,500,000	39,024,000
Other long-term liabilities	3,317,000	3,204,000
Shareholders’ equity:
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	0	0
Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 37,253,771 and 37,152,979 shares, respectively	372,000	371,000
Additional paid-in capital	178,760,000	163,306,000
Retained earnings	(770,553,000)	(713,851,000)
Accumulated other comprehensive (loss) income	70,405,000	30,593,000
Total shareholders’ equity	879,280,000	846,935,000
	$ 1,129,581,000	$ 1,063,360,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Allowance for doubtful accounts	$ 555	$ 487
Undesignated capital stock, no par (in dollars per share)	$ 0	$ 0
Undesignated capital stock, shares authorized (in shares)	5,000,000	5,000,000
Undesignated capital stock, shares issued (in shares)	0	0
Undesignated capital stock, shares outstanding (in shares)	0	0
Common stock authorized (in shares)	100,000,000	100,000,000
Common stock issued (in shares)	37,253,771	37,152,979
Common stock outstanding (in shares)	37,253,771	37,152,979
Common stock par value (in dollars per share)	$ 0.01	$ 0.01

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Jun. 30, 2013	36,835,000
Balances at Jun. 30, 2013	$ 368,000	$ 134,895,000	$ 587,725,000	$ 14,553,000	$ 737,541,000
Net earnings			110,948,000		110,948,000
Other comprehensive loss				(19,941,000)	(19,941,000)
Surrender and retirement of stock to exercise options (in shares)	(1,000)
Surrender and retirement of stock to exercise options	$ 0	(56,000)			$ (56,000)
Common stock issued for exercise of options (in shares)	142,000				142
Common stock issued for exercise of options	$ 2,000	8,380,000			$ 8,382,000
Common stock issued for restricted stock awards (in shares)	26,000
Common stock issued for restricted stock awards	$ 0				0
Cash dividends			(45,394,000)		(45,394,000)
Stock-based compensation expense		3,523,000			3,523,000
Tax benefit from exercise of stock options		262,000			262,000
Balances (in shares) at Jun. 30, 2014	37,002,000
Balances at Jun. 30, 2014	$ 370,000	147,004,000	653,279,000	(5,388,000)	795,265,000
Net earnings			107,735,000		107,735,000
Other comprehensive loss				(25,205,000)	(25,205,000)
Surrender and retirement of stock to exercise options (in shares)	0
Surrender and retirement of stock to exercise options	$ 0	(31,000)			$ (31,000)
Common stock issued for exercise of options (in shares)	141,000				141
Common stock issued for exercise of options	$ 1,000	9,761,000			$ 9,762,000
Common stock issued for restricted stock awards (in shares)	10,000
Common stock issued for restricted stock awards	$ 0		(57,000)		(57,000)
Cash dividends			(47,106,000)		(47,106,000)
Stock-based compensation expense		5,918,000			5,918,000
Tax benefit from exercise of stock options		615,000			$ 615,000
Balances (in shares) at Jun. 30, 2015	37,153,000				37,152,979
Balances at Jun. 30, 2015	$ 371,000	163,306,000	713,851,000	(30,593,000)	$ 846,935,000
Employee stock purchase plan expense		39,000			39,000
Net earnings			104,476,000		104,476,000
Other comprehensive loss				(39,812,000)	(39,812,000)
Surrender and retirement of stock to exercise options (in shares)	0
Surrender and retirement of stock to exercise options	$ 0	(31,000)			$ (31,000)
Common stock issued for exercise of options (in shares)	69,000				69
Common stock issued for exercise of options	$ 1,000	4,796,000			$ 4,797,000
Common stock issued for restricted stock awards (in shares)	23,000
Common stock issued for restricted stock awards	$ 0		(167,000)		(167,000)
Cash dividends			(47,607,000)		(47,607,000)
Stock-based compensation expense		9,287,000			9,287,000
Tax benefit from exercise of stock options		566,000			$ 566,000
Balances (in shares) at Jun. 30, 2016	37,254,000				37,253,771
Balances at Jun. 30, 2016	$ 372,000	178,760,000	770,553,000	(70,405,000)	$ 879,280,000
Employee stock purchase plan expense		144,000			144,000
Common stock issued to employee stock purchase plan (in shares)	9,000
Common stock issued to employee stock purchase plan		$ 692,000			$ 692,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net earnings	$ 104,476,000	$ 107,735,000	$ 110,948,000
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	42,764,000	37,226,000	19,175,000
Costs recognized on sale of acquired inventory	5,431,000	6,961,000	7,480,000
Deferred income taxes	(2,624,000)	1,304,000	(2,853,000)
Stock-based compensation expense	9,430,000	5,957,000	3,523,000
Gain on sale of CyVek	0	(8,300,000)	0
Excess tax benefit from stock option exercises	(566,000)	(615,000)	(262,000)
Other	0	458,000	592,000
Change in operating assets and liabilities, net of acquisitions:
Trade accounts and other receivables	(22,981,000)	(11,747,000)	1,145,000
Inventories	(6,626,000)	(4,714,000)	(2,895,000)
Prepaid expenses	(381,000)	(620,000)	(554,000)
Trade accounts payable and accrued expenses	8,924,000	2,154,000	1,368,000
Salaries, wages and related accruals	5,725,000	1,679,000	1,034,000
Income taxes payable	298,000	1,881,000	(1,939,000)
Net cash provided by operating activities	143,870,000	139,359,000	136,762,000
Cash flows from investing activities:
Purchase of available-for-sale investments	0	0	(106,746,000)
Proceeds from sale and maturities of available-for-sale investments	776,000	13,466,000	289,410,000
Additions to property and equipment	(16,898,000)	(19,905,000)	(13,821,000)
Acquisitions, net of cash acquired	(91,423,000)	(420,102,000)	(109,180,000)
Investment in unconsolidated entity	0	0	(10,000,000)
Other	(25,000)	48,000	25,000
Net cash used in investing activities	(107,570,000)	(426,493,000)	49,688,000
Cash flows from financing activities:
Cash dividends	(47,607,000)	(47,107,000)	(45,394,000)
Proceeds from stock option exercises	5,458,000	9,731,000	8,326,000
Excess tax benefit from stock option exercises	566,000	615,000	262,000
Borrowings under line-of-credit agreement	77,000,000	163,000,000	0
Payment on line-of-credit and other	(58,500,000)	(94,964,000)	0
Net cash used in financing activities	(23,083,000)	(31,276,000)	(36,806,000)
Effect of exchange rate changes on cash and cash equivalents	(3,512,000)	(8,178,000)	5,138,000
Net change in cash and cash equivalents	9,705,000	(264,036,000)	154,782,000
Cash and cash equivalents at beginning of year	54,532,000	318,568,000	163,786,000
Cash and cash equivalents at end of year	$ 64,237,000	$ 54,532,000	$ 318,568,000

Note 1 - Description of Busines

Note 1 - Description of Business and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	Note 1. Description of Business and Summary of Significant Accounting Policies: Description of business: Estimates: Principles of consolidation: Translation of foreign financial statements: Revenue recognition: Research and development: Advertising costs: Share-based compensation: Income taxes: In November 2015, the FASB issued ASU 2015-17, "Income Taxes: Balance Sheet Classification of Deferred Taxes." ASU 2015-17 requires that deferred income tax liabilities and assets be classified as non-current in a statement of financial position. The Company elected early adoption of this guidance during the quarter ended March 31, 2016, on a prospective basis. The adoption of this ASU allows the Company to simplify its presentation of deferred income tax liabilities and assets. Prior periods were not retrospectively adjusted. Financial instruments not measured at fair value: Cash and equivalents: Available-for-sale investments: Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. Unrealized gains and losses on available-for-sale securities are excluded from income, but are included, net of taxes, in other comprehensive income. If an “other-than-temporary” impairment is determined to exist, the difference between the value of the investment security recorded in the financial statements and the Company’s current estimate of the fair value is recognized as a charge to earnings in the period in which the impairment is determined. Inventories: Property and equipment: Goodwill: Intangible assets: Investments in unconsolidated entities:

Note 2 - Acquisitions

Note 2 - Acquisitions	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 2. Acquisitions: Zephyrus Biosciences, Inc. On March 14, 2016, the Company acquired Zephyrus Biosciences, Inc. (Zephyrus) for $8 million in cash and up to $7 million in contingent consideration. Zephyrus provides research tools to enable protein analysis at the single cell level. Addressing the burgeoning single cell analysis market, Zephyrus's first product, Milo™, enables western blotting on individual cells for the first time. The acquisition was funded with cash on hand. The purchase price of Zephyrus exceeded the preliminary estimated fair value of the identifiable net assets and, accordingly, the difference was allocated to goodwill, substantially all of which is not tax deductible. Zephryus is included in the Company's Protein Platforms segment. In connection with the Zephyrus acquisition, the Company recorded $7.4 million of in process research and development which is not amortized until it is converted to developed technology which occurs once a sale of its product is completed. The intangible asset amortization for the developed technology is not deductible for income tax purposes. Of further note the purchase accounting for this acquisition is still open and has not been finalized. The Company will pay Zephyrus former shareholders and additional $3.5 million if and when 10 instruments are sold prior to the 3 year anniversary of the closing date (March 14, 2019). In addition, the Company will pay Zephyrus former shareholders an additional $3.5 million if and when $3 million in cumulative sales are generated within 4.5 yrs of the closing date (September 14, 2020). We have established an initial estimate of the fair value of these contingent consideration payments to be $3.5 million in total. The Company is still in the process of finalizing the purchase accounting related to this acquisition. The goodwill recorded as a result of the Zephyrus acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration from future products and customers. The goodwill is not deductible for income tax purposes. Cliniqa Corporation On July 8, 2015, the Company acquired Cliniqa Corporation (Cliniqa) for approximately $83 million. Cliniqa specializes in the manufacturing and ommercialization of blood chemistry quality controls and calibrators as well as bulk reagents used for the clinical diagnostic market to further expand and complement our Clinical Controls solutions. The acquisition was funded with a cash on hand and with funds obtained from our revolving credit facility. The purchase price of Cliniqa exceeded the fair value of the identifiable net assets and, accordingly, the difference was allocated to goodwill. Cliniqa is included in the Company’s Clinical Controls segment. In connection with the Cliniqa acquisition, the Company recorded $18 million of developed technology intangible assets that have an estimated useful life of 14 years, $27 million of customer relationship intangible assets that have an estimated useful life of 13 years, and $1.1 million related to trade mark and trade names with a useful life of 4 years. The intangible asset amortization is not deductible for income tax purposes. The goodwill recorded as a result of the Cliniqa acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration from future products and customers. The goodwill is not deductible for income tax purposes. CyVek Inc On November 3, 2014, the Company acquired CyVek, Inc. (CyVek) through a merger. CyVek has developed a transformative immunoassay technology which integrates an innovatively designed microfluidic cartridge with a state-of-the-art analyzer to deliver the most advanced and efficient bench top immunoassay system. In fiscal 2014, the Company entered into an Agreement of Investment and Merger (the Agreement) with CyVek. Pursuant to the terms of the Agreement, the Company invested $10.0 million in CyVek and received shares of Common Stock representing approximately 19.9% of the outstanding voting stock of CyVek. Between the time of the Company’s initial investment and November 3, 2014, CyVek met certain commercial milestones related to the sale of its products, which obligated the Company to acquire CyVek through a merger, with CyVek surviving as a wholly-owned subsidiary of the Company. The Company made an initial payment of approximately $62.0 million to the other stockholders of CyVek on November 3, 2014. Such purchase price was adjusted after closing based on the final levels of cash, indebtedness and transaction expenses of CyVek as of the closing. The Company will also pay CyVek’s previous stockholders up to $35.0 million based on the revenue generated by CyVek’s products before December 31, 2017. The Company will also pay CyVek’s previous stockholders 50% of the amount, if any, by which the revenue from CyVek’s products and related products exceeds $100 million in calendar year 2020. The Company has recorded the present value of these contingent payments as a long-term liability of $35.0 million at June 30, 2016 and 2015. In addition, at November 3, 2014, the Company remeasured its previous investment in CyVek to acquisition-date fair value, resulting in a gain on the investment of $8.3 million which is included in Other income on the Condensed Consolidated Statements of Earnings and Comprehensive Income. The purchase price of CyVek exceeded the fair value of the identifiable net assets and, accordingly, the difference was allocated to goodwill, substantially all of which is not tax deductible. CyVek is included in the Company’s Protein Platforms segment. In connection with the CyVek acquisition, the Company recorded $20.2 million of developed technology intangible assets that have an estimated useful life of 15 years, $0.1 million of trade name intangible assets that have an estimated useful life of 1.5 years, and $0.6 million related to customer relationships that have an estimated useful life of 10 years. The intangible asset amortization is not deductible for income tax purposes. The goodwill recorded as a result of the CyVek acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration from future products and customers. The goodwill is not deductible for income tax purposes. Transaction costs of $0.1 million were included in the Company’s selling, general and administrative costs during fiscal 2015 related to the CyVek acquisition. ProteinSimple On July 31, 2014, the Company acquired ProteinSimple. ProteinSimple expands the Company’s solutions that it can offer its customers by developing and commercializing proprietary systems and consumables for protein analysis. The Company opened a line-of-credit (Note 7) to partially fund the acquisition. The purchase price of ProteinSimple exceeded the fair value of the identifiable net assets and, accordingly, the difference was allocated to goodwill. ProteinSimple is included in the Company’s Protein Platform segment. In connection with the ProteinSimple acquisition, the Company recorded $39.2 million of developed technology intangible assets that have an estimated useful lives of 9-10 years, $36.1 million of trade name intangible assets that have an estimated useful lives of 18-20 years, $101.6 million related to customer relationships that have estimated useful lives of 14-16 years, and $0.2 million related to non-compete agreements that have an estimated useful life of 3 years. The intangible asset amortization is not deductible for income tax purposes. The goodwill recorded as a result of the ProteinSimple acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration from future products and customers. The goodwill is not deductible for income tax purposes. Transaction costs of $0.8 million were included in the Company’s selling, general and administrative costs during fiscal 2015 related to the ProteinSimple acquisition. Novus Holdings LLC On July 2, 2014, the Company acquired all of the issued and outstanding equity interests of Novus Holdings LLC (Novus). Novus broadens the Company’s antibody offerings by being a supplier of a large portfolio of both outsourced and in-house developed antibodies and other reagents for life science research. Novus is included in the Company’s Biotechnology segment. In connection with the Novus acquisition, the Company recorded $5.0 million of developed technology intangible assets that have estimated useful lives of 4-12 years, $5.3 million of trade name intangible assets that have an estimated useful life of 20 years, and $14.4 million related to customer relationships that have an estimated useful life of 15 years. The majority of the intangible asset amortization is not deductible for income tax purposes. The goodwill recorded as a result of the Novus acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration from future products and customers. The majority of the goodwill is not deductible for income tax purposes. Transaction costs of $0.1 million were included in the Company’s selling, general and administrative costs during fiscal 2015 related to the Novus acquisition. Shanghai PrimeGene Bio-Tech Co. On April 30, 2014, the Company acquired all of the ownership interest of Shanghai PrimeGene Bio-Tech Co. (PrimeGene). PrimeGene manufactures recombinant proteins and is included in the Company’s Biotechnology segment. The Company paid approximately $6.0 million at closing, with the remaining purchase price payable over fiscal years 2015 to 2017. The note payable is due to individuals who are currently employed by PrimeGene. In connection with the PrimeGene acquisition, the Company recorded $2.2 million of developed technology intangible assets that have an estimated useful life of 9 years, $3.0 million of trade name intangible assets that have an estimated useful life of 11 years, $0.3 million related to non-compete agreements that have an estimated useful life of 3 years, and $9.1 million related to customer relationships that have an estimated useful life of 9 years. The intangible asset amortization is not deductible for income tax purposes. The goodwill recorded as a result of the PrimeGene acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration from future products and customers. The goodwill is not deductible for income tax purposes. Transaction costs of $0.4 million were included in the Company’s selling, general and administrative costs during fiscal 2014, related to the PrimeGene acquisition. Bionostics Holdings, Ltd On July 22, 2013, the Company acquired for cash all of the outstanding shares of Bionostics Holdings, Ltd. (Bionostics) and its U.S. operating subsidiary, Bionostics, Inc. Bionostics is a global leader in the development, manufacture and distribution of control solutions that verify the proper operation of in-vitro diagnostic devices primarily utilized in point of care blood glucose and blood gas testing. Bionostics is included in the Company’s Clinical Controls segment. In connection with the Bionostics acquisition, the Company recorded $14.4 million of developed technology intangible assets that have an estimated useful life of 9 years, $2.7 million of trade name intangible assets that have an estimated useful life of 5 years, $2.4 million related to non-compete agreements that have an estimated useful life of 3 years, and $41.0 million related to customer relationships that have an estimated useful life of 14 years. The intangible asset amortization is not deductible for income tax purposes. The goodwill recorded as a result of the Bionostics acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration from future products and customers. The goodwill is not deductible for income tax purposes. Transaction costs of $0.5 million and $0.6 million were included in the Company’s selling, general and administrative costs during fiscal 2014 and 2013, respectively, related to the Bionostics acquisition. The aggregate purchase price of the acquisitions was allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the acquisitions (in thousands): Zephyrus Cliniqa Novus Protein Simple CyVek Bionostics PrimeGene Current assets $ 86 $ 11,926 $ 10,739 $ 19,660 $ 1,206 $ 9,605 $ 1,272 Equipment 32 1,436 1,266 1,983 971 2,180 546 Other long-term assets 58 40 554 19 Intangible Assets: In process research and development 7,400 - - - - - - Developed technology - 18,000 5,010 39,200 20,200 14,400 2,200 Trade name - 1,100 5,300 36,100 100 2,700 3,000 Customer relationships - 27,000 14,400 101,600 600 41,000 9,100 Non-compete agreements - - - 200 - 2,400 322 Goodwill 6,878 42,669 28,408 134,074 91,658 56,349 5.518 Total assets acquired 14,396 102,189 65,163 333,371 114,754 128,634 21,958 Liabilities 54 1,508 2,166 11,644 1,965 3,007 887 Deferred income taxes, net 2,812 17,793 2,875 21,674 (438 ) 22,478 2,310 Net assets 11,530 82,888 $ 60,122 $ 300,053 $ 113,227 $ 103,149 $ 18,761 Less fair-value of previous investment - - - - 18,300 - - Net assets acquired 11,530 82,888 60,122 300,053 94,927 103,149 18,761 Cash paid, net of cash acquired $ 8,030 $ 82,888 $ 60,122 $ 300,053 $ 59,927 $ 103,149 $ 6,031 Note Payable 0 0 0 0 0 0 12,730 Contingent consideration payable 3,500 - - - 35,000 - - Net purchase price $ 11,530 $ 82,888 $ 60,122 $ 300,053 $ 94,927 $ 103,149 $ 18,761 Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management’s assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management’s forecasted cash inflows and outflows and using a relief-from-royalty and a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, of which are not deductible for income tax purposes, and the future tax benefit of net operating loss and tax credit carryforwards which will be deductible by the Company in future periods.

Note 3 - Available-for-sale Inv

Note 3 - Available-for-sale Investments	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	Note 3. Available-For-Sale Investments: At June 30, 2016 and 2015, the cost and market value of the Company’s available-for-sale securities by major security type were as follows (in thousands): June 30, 201 6 201 5 Cost Market Cost Market Certificates of deposit $ 3,016 $ 3,017 $ 4,089 $ 4,089 Equity securities 29,472 28,581 29,472 52,300 $ 32,488 $ 31,598 $ 33,561 $ 56,389 At June 30, 2016 and 2015, all of the Company’s equity securities which relates to our investment in CCXI stock and warrants, were valued using Level 1 inputs. Certificates of deposit are carried at cost and are not subject to the fair value hierarchy. There were no transfers between Level 1 and Level 2 securities during fiscal 2016. Gross unrealized gains (losses) on available-for-sale investments were $(0.9) million and $22.8 million at June 30, 2016, and June 30, 2015, respectively. The unrealized loss on available-for-sale investments for the twelve months ended June 30, 2016 includes $0.9 million of unrealized gross losses related to our investment in CCXI. As of June 30, 2016, the stock price of CCXI was $4.49 per share compared to our cost basis of $4.73 per share. Based upon our analysis, we believe there is insufficient information to conclude that the impairment of our investment in CCXI is other-than-temporary. As such, we have concluded that the impairment is temporary and have classified the impairment within other comprehensive income.

Note 4 - Inventories

Note 4 - Inventories	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 4. Inventories: Inventories consist of (in thousands): June 30, 201 6 201 5 Raw materials $ 22,963 $ 15,892 Finished goods 34,139 33,685 $ 57,102 $ 49,577 At June 30, 2016 and 2015, the Company had $23.4 million and $24.0 million, respectively, of excess protein, antibody and chemically-based inventory on hand which was not valued.

Note 5 - Property and Equipment

Note 5 - Property and Equipment	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 5. Property and Equipment: Property and equipment consist of (in thousands): June 30, 201 6 201 5 Cost: Land $ 6,270 $ 7,370 Buildings and improvements 157,963 156,965 Machinery, equipment and other 82,018 74,385 246,251 238,720 Accumulated depreciation and amortization (113,889 ) (108,967 ) $ 132,362 $ 129,749

Note 6 - Intangibles Assets and

Note 6 - Intangibles Assets and Goodwill	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	Note 6. Intangible Assets and Goodwill: Intangible assets and goodwill consist of (in thousands): June 30, Useful Life (years) 201 6 201 5 Developed technology 8 - 15 $ 120,611 $ 108,887 Trade names 5 - 16 63,706 63,867 Customer relationships 8 - 16 191,118 167,494 Non-compete agreement 3 - 5 3,284 3,298 378,719 343,546 Accumulated amortization (75,595 ) (50,707 ) Total amortizeable intagibles $ 303,124 $ 292,839 In process research and development 7,400 0 Total intangible assets 310,524 292,839 Goodwill $ 430,882 $ 390,638 Changes to the carrying amount of goodwill consists of (in thousands): Year Ended June 30, 201 6 201 5 Beginning balance $ 390,638 $ 151,473 Acquisitions 49,648 254,140 Currency translation (9,404 ) (14,975 ) Ending balance $ 430,882 $ 390,638 Changes to the carrying amount of net intangible assets consists of (in thousands): Year Ended June 30, 201 6 201 5 Beginning balance $ 292,839 $ 108,776 Acquisitions 53,500 222,710 Amortization expense (29,395 ) (26,170 ) Currency translation (6,420 ) (12,777 ) Ending balance $ 310,524 $ 292,839 Amortization expense related to technologies included in cost of sales was $11.1 million $9.5 million, and $4.2 million in fiscal 2016, 2015, and 2014, respectively. Amortization expense related to trade names, customer relationships, and the non-compete agreement included in selling, general and administrative expense was $18.3 million, $16.7 million, and $6.1 million, in fiscal 2016, 2015, and 2014 respectively. The estimated future amortization expense for intangible assets as of June 30, 2016 is as follows (in thousands): Year Ending June 30: 2017 28,326 2018 28,140 2019 27,527 2020 26,898 2021 26,534 Thereafter 165,699 $ 303,124

Note 7 - Debt and Other Financi

Note 7 - Debt and Other Financing Arrangements	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 7. Debt and Other Financing Arrangements: On July 28, 2014, the Company entered into a revolving line-of-credit facility governed by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $150 million, which can be increased by an additional $150 million subject to certain conditions. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement for base rate loans bear interest at a variable rate equal to the greater of (i) the prime commercial rate, (ii) the per annum federal funds rate plus 0.5%, or (iii) LIBOR + 1.00% - 1.75% depending on the existing total leverage ratio of Debt to Earnings Before Interest, Taxes, Depreciation and Amortization (as defined in the Credit Agreement). The annualized fee for any unused portion of the credit facility is 15 basis points. The Credit Agreement would have matured on July 31, 2019 and contains customary restrictive and financial covenants and customary events of default. As of June 30, 2016, the outstanding balance under the Credit Agreement was $91.5 million. In connection with the acquisition of Advanced Cell Diagnostics on August 1, 2016, the Company entered into a new revolving credit facility governed by a Credit Agreement dated July 28, 2016. This facility replaced the revolving line-of-credit facility mentioned above. This new Credit Agreement provides for a revolving credit facility of $400 million. Borrowings under the Credit Agreement bear interest at a variable rate.

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 8. Commitments and Contingencies: The Company leases office and warehouse space, vehicles and various office equipment under operating leases. At June 30, 2016, aggregate net minimum rental commitments under non-cancelable leases having an initial or remaining term of more than one year are payable as follows (in thousands): Year Ending June 30: 2017 6,326 2018 5,801 2019 4,810 2020 4,761 2021 4,815 Thereafter 19,120 $ 45,633 Total rent expense was approximately $8.1 million, $4.9 million, and $1.6 million for the years ended June 30, 2016, 2015, and 2014, respectively. The Company is routinely subject to claims and involved in legal actions which are incidental to the business of the Company. Although it is difficult to predict the ultimate outcome of these matters, management believes that any ultimate liability will not materially affect the consolidated financial position or results of operations of the Company.

Note 9 - Share-based Compensati

Note 9 - Share-based Compensation and Other Benefit Plans	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 9. Share-based Compensation and Other Benefit Plans: Equity incentive plan: Stock option activity under the Plans for the three years ended June 30, 2016, consists of the following (shares in thousands): Shares Weighted Weighted Aggregate (millions) Outstanding at June 30, 2013 728 66.70 Granted 251 80.88 Forfeited (26 ) 76.23 Exercised (142 ) 59.07 Outstanding at June 30, 2014 811 72.11 Granted 600 93.98 Forfeited (133 ) 92.85 Exercised (141 ) 69.31 Outstanding at June 30, 2015 1,137 81.57 Granted 805 105.16 Forfeited (54 ) 99.68 Exercised (69 ) 69.82 Outstanding at June 30, 2016 1,819 $ 91.91 5.3 $ 37.9 Exercisable at June 30: 2014 534 $ 69.49 2015 547 72.72 2016 596 75.74 4.2 $ 22.1 The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used: Year Ended June 30, 201 6 201 5 201 4 Dividend yield 1.2% 1.3% 1.5% Expected volatility 20% - 23% 18% - 21% 18% - 22% Risk-free interest rates 1.2% - 1.9% 1.3% - 2.2% 1.4% - 2.1% Expected lives (years) 5 5 6 The dividend yield is based on the Company’s historical annual cash dividend divided by the market value of the Company’s common stock. The expected annualized volatility is based on the Company’s historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted. The weighted average fair value of options granted during fiscal 2016, 2015 and 2014 was $18.50, $15.01 and $14.77 respectively. The total intrinsic value of options exercised during fiscal 2016, 2015 and 2014 were $2.4 million, $3.5 million, and $3.7 million respectively. The total fair value of options vested during fiscal 2016, 2015 and 2014 were $1.6 million, $2.3 million, and $2.2 million respectively. In fiscal 2016, 2015 and fiscal 2014, 19,994, 9,000, and 26,355 restricted common stock shares were granted at weighted average grant date fair values of $99.53, $91.78, and $86.60 per share, respectively. Non-vested restricted common stock shares at June 30, 2016, 2015 and 2014 were 22,545, 19,102, and 36,355 respectively. In fiscal 2016, 2015 and 2014, 35,083, 36,192, and 5,000 restricted stock units were granted at a weighted average grant date fair value of $105.01 and $94.13, respectively. The restricted stock units vest over a three year period. In fiscal 2016, 10,000 restricted stock units were forfeited. Stock-based compensation cost of $9.4 million, $5.9 million and $3.5 million was included in selling, general and administrative expense in fiscal 2016, 2015 and 2014, respectively. As of June 30, 2016, there was $15.9 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock which will be expensed in fiscal 2017 through 2020. The weighted average period over which the compensation cost is expected to be recognized is 1.2 years. Employee stock purchase plan: Profit sharing and savings plans:  Performance incentive programs:

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 10. Income Taxes: The provisions for income taxes consist of the following (in thousands): Year Ended June 30, 201 6 201 5 201 4 Earnings before income taxes consist of: Domestic $ 120,154 $ 121,765 $ 127,681 Foreign 27,327 32,397 33,711 $ 147,481 $ 154,162 $ 161,392 Taxes on income consist of: Currently payable: Federal $ 34,805 $ 28,220 $ 40,967 State 2,958 6,165 1,709 Foreign 7,579 10,704 10,668 Net deferred: Federal 1,906 4,401 (1,137 ) State (428 ) 292 (41 ) Foreign (3,815 ) (3,355 ) (1,722 ) $ 43,005 $ 46,427 $ 50,444 The following is a reconciliation of the federal tax calculated at the statutory rate of 35% to the actual income taxes provided (in thousands): Year Ended June 30, 201 6 201 5 201 4 Computed expected federal income tax expense $ 51,618 $ 53,957 $ 56,487 State income taxes, net of federal benefit 1,852 4,762 1,048 Qualified production activity deduction (3,932 ) (3,140 ) (3,823 ) Non-taxable gain on investment 0 (2,905 ) 0 Research and development tax credit (1,550 ) (912 ) (476 ) Tax-exempt interest 0 0 (654 ) Foreign tax rate differences (4,639 ) (4,059 ) (2,857 ) Other (344 ) (1,276 ) 719 $ 43,005 $ 46,427 $ 50,444 The effective rate for June 30, 2016 decreased by 0.9% compared to the prior year. The rate decrease was primarily driven by additional R&D credit benefit due to the retroactive reinstatement of the credit under the Protecting Americans from Tax Hikes Act of 2015, an increase in the foreign rate benefit due to the reduction in the UK income tax rate and a reduction in state tax related to the prior year. These decreases were partially offset by less of a foreign tax credit benefit than in the prior year and the non recurrence of a non-taxable gain. In the year ended June 30, 2015, as a result of the recent acquisitions, the rate reflects an increase for state tax expense as well as a resulting provision to return true up from fiscal 2014. This increase is offset by the non-taxable gain which was a result of purchasing the remaining interest in CyVek. In addition the Company‘s R&D Europe subsidiary declared and paid a dividend of £46.6 million which resulted in a tax benefit of approximately $1.7 million. Temporary differences comprising deferred taxes on the Consolidated Balance Sheets are as follows (in thousands): June 30 201 6 201 5 Inventory $ 9,768 $ 8,753 Net operating loss carryovers 26,556 34,767 Tax credit carryovers 3,197 3,872 Excess tax basis in equity investments 4,544 4,496 Deferred compensation 5,912 3,747 Net unrealized loss on available for sale investment 329 0 Other 7,421 4,712 Valuation allowance (7,201 ) (2,558 ) Net deferred tax assets 50,526 57,789 Net unrealized gain on available-for-sale investments 0 (8,446 ) Intangible asset amortization (107,200 ) (96,401 ) Depreciation (5,132 ) (2,394 ) Other (1,031 ) (466 ) Deferred tax liabilities (113,363 ) (107,707 ) Net deferred tax liabilities $ (62,837 ) $ (49,918 ) A deferred tax valuation allowance is required when it is more likely than not that all or a portion of deferred tax assets will not be realized. At June 30, 2016, a valuation allowance for potential capital loss carryovers on equity investments was $5.0 million. Approximately $2.0 million of the valuation allowance at June 30, 2016 is for certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company acquired Novus, ProteinSimple, and CyVek. The remainder of the valuation allowance is for certain state tax credit carryovers generated in fiscal 2016 and 2015. The Company believes it is more likely than not that these tax carryovers will not be realized. At June 30, 2015, a valuation allowance for potential capital loss carryovers on equity investments was zero. Approximately $2.4 million of the valuation allowance at June 30, 2015 was for acquisition related foreign and state tax net operating loss and state credit carryforwards. The remainder of the valuation allowance was for certain state tax credit carryovers generated in fiscal 2015. The valuation allowance as of June 30, 2016 was $7.2 million which is an increase of $4.7 million over prior year. This increase included a $5.0 million change related to an investment and was recorded through other comprehensive income and was partially offset by a decrease of $0.3 million primarily related to the utilization of expiation of state net operating loss carry forwards and research and development credits. At June 30, 2016, the Company has federal and state net operating loss carryforwards of approximately $63.9 million and $71.6 million, respectively, from its fiscal 2015 acquisitions of ProteinSimple and CyVek, which are not limited under IRC Section 382. At June 30, 2016, the Company has foreign net operating loss carryforwards of $2.1 million from its fiscal 2015 acquisition of Novus. The net operating loss carryforwards expire between fiscal 2017 and 2034. The Company has a deferred tax asset of $24.9 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. At June 30, 2016, the Company has federal and state tax credit carryforwards of $1.7 million and $1.3 million, respectively. The federal tax credit carryforwards expire between 2018 and 2035. The state credit carryforwards have no expiry date. The Company has a deferred tax asset of $3.6 million, net of the valuation allowance discussed above, related to the tax credit carryovers. The Company has not recognized a deferred tax liability for unremitted earnings of approximately $57.6 million from its foreign operations because its subsidiaries have invested or will invest the undistributed earnings indefinitely, or the earnings will be remitted in a tax-neutral transaction. Generally, such amounts become subject to United States taxation upon the remittance of dividends and under other circumstances. It is not practical to estimate the amount of the deferred income tax liabilities related to investments in these foreign subsidiaries. The Company’s unrecognized tax benefits at June 30, 2016, 2015 and 2014, including accrued interest and penalties, were not material. The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next twelve months. The Company files income tax returns in the U.S federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company’s federal returns are subject to tax assessment for 2013 and subsequent years. State and foreign income tax returns are generally subject to examination for a period of three to five years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to one year after formal notification to the states.

Note 11 - Earnings Per Share

Note 11 - Earnings Per Share	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 11. Earnings Per Share: The number of shares used to calculate earnings per share are as follows (in thousands, except per share data): Year Ended June 30, 201 6 201 5 201 4 Net earnings used for basic and diluted earnings per share $ 104,476 $ 107,735 $ 110,948 Weighted average shares used in basic computation 37,194 37,096 36,890 Dilutive stock options 132 135 115 Weighted average shares used in diluted computation 37,326 37,231 37,005 Basic EPS $ 2.81 $ 2.90 $ 3.01 Diluted EPS $ 2.80 $ 2.89 $ 3.00 The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 1.2 million, 516,000 and 196,000 at June 30, 2016, 2015 and 2014, respectively.

Note 12 - Segment Information

Note 12 - Segment Information	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 12. Segment Information: The Company has three reportable segments based on the nature of its products; they are Biotechnology, Clinical Controls, and Protein Platforms. The Company’s Biotechnology reporting segment develops, manufactures and sells biotechnology research and diagnostic products world-wide. No customer in the Biotechnology segment accounted for more than 10% of the segments' net sales for the years ended June 30, 2016, 2015, and 2014,. The Company’s Clinical Controls reporting segment develops and manufactures controls and calibrators for sale world-wide. One customer accounted for approximately, 13%, and 14% of Clinical Controls’ net sales during fiscal 2015, and 2014 respectively. One customer did not account for net sales over 10% during 2016. The Company’s Protein Platforms segment develops and commercializes proprietary systems and consumables for protein analysis. This segment was formed from the fiscal 2015 acquisitions of ProteinSimple and CyVek. No customer in the Protein Platforms segment accounted for more than 10% of the segments net sales for the years ended June 30, 2016 and 2015. There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term. Following is financial information relating to the operating segments (in thousands): Year Ended June 30, 201 6 201 5 201 4 External sales Biotechnology $ 317,340 $ 308,437 $ 285,142 Clinical Controls 104,484 77,866 72,621 Protein Platforms 77,324 66,249 0 Inter segment (125 ) (306 ) 0 Consolidated net sales $ 499,023 $ 452,246 $ 357,763 Year Ended June 30, 201 6 201 5 201 4 Operating Income Biotechnology $ 168,613 $ 165,226 $ 162,621 Clinical Controls 30,412 23,981 22,976 Protein Platforms 3,592 4,469 0 Segment operating income 202,617 193,676 185,597 Costs recognized upon sale of acquired inventory (5,431 ) (6,952 ) (7,480 ) Amortization of intangibles (29,395 ) (26,169 ) (10,276 ) Stock based compensation (9,430 ) (5,957 ) (3,523 ) Acquisition related expenses (2,761 ) (4,519 ) (2,247 ) Corporate general, selling and administrative expenses (5,007 ) (3,056 ) (2,321 ) Consolidated operating income $ 150,593 $ 147,023 $ 159,750 Goodwill Biotechnology $ 105,380 $ 115,198 $ 90,872 Clinical Controls 106,692 60,601 60,601 Protein Platforms 218,810 214,839 0 Consolidated goodwill $ 430,882 $ 390,638 $ 151,473 Intangible assets, net Biotechnology $ 57,199 $ 68,777 $ 53,778 Clinical Controls 86,736 49,130 54,998 Protein Platforms 166,589 174,932 0 Consolidated intangible assets, net $ 310,524 $ 292,839 $ 108,776 Assets Biotechnology $ 387,470 $ 430,524 $ 674,854 Clinical Controls 212,649 74,954 66,072 Protein Platforms 440,343 444,899 0 Segment assets 1,040,462 950,378 740,917 Corporate cash and available- for- sale investments 31,255 52,800 60,142 Corporate property and equipment 56,195 58,270 60,350 Corporate, other 1,669 1,912 1,082 Consolidated assets $ 1,129,581 $ 1,063,360 $ 862,491 Depreciation and amortization Biotechnology $ 14,196 $ 13,820 $ 10,879 Clinical Controls 10,462 7,963 7,205 Protein Platforms 16,027 13,364 0 Segment depreciation and amortization 40,685 35,147 18,084 Corporate 2,079 2,079 1,091 Consolidated depreciation and amortization $ 42,764 $ 37,226 $ 19,175 Capital purchases Biotechnology $ 14,295 $ 9,794 $ 4,157 Clinical Controls 1,780 1,932 5,687 Protein Platforms 823 8,179 Segment capital purchases 16,898 19,905 9,844 Corporate 0 0 3,977 Consolidated capital purchases $ 16,898 $ 19,905 $ 13,821 The other reconciling items include the results of unallocated corporate expenses and the Company’s share of gain (losses) from its equity method investees. Following is financial information relating to geographic areas (in thousands): Year Ended June 30, 201 6 201 5 201 4 External sales United States $ 283,270 $ 245,217 $ 190,359 U.K. 88,680 68,055 55,144 Other Europe 51,047 66,022 42,013 China 27,205 26,105 18,878 Other Asia 24,809 23,806 32,704 Rest of world 24,012 23,041 18,665 Total external sales $ 499,023 $ 452,246 $ 357,763 Long-lived assets United States and Canada $ 118,027 $ 119,075 $ 109,790   Europe 14,423 11,239 8,340 China 1,109 1,286 678 Total long-lived assets $ 133,559 $ 131,600 $ 118,808 External sales are attributed to countries based on the location of the customer or distributor. Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.

Note 13 - Supplemental Disclosu

Note 13 - Supplemental Disclosures of Cash Flow Information and Noncash Investing and Financing Activities	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	Note 13. Supplemental Disclosures of Cash Flow Information and Noncash Investing and Financing Activities: In fiscal 2016, the Company acquired Cliniqa and Zephyrus for approximately $83 million and $11.5 million, respectively. Zephyrus was acquired for approximately $8 million in cash plus additional contingent consideration with a fair value of $3.5 million. In fiscal 2015, the Company acquired Novus, ProteinSimple, and CyVek for approximately $60 million, $300 million and $95 million, respectively. CyVek was acquired for approximately $62 million in cash and the Company will also pay CyVek’s previous stockholders up to $35.0 million based on the revenue generated by CyVek’s products before May 3, 2017 (30 months from the closing of the Merger). In fiscal 2014, the Company acquired Bionostics for approximately $103 million. PrimeGene was acquired for approximately $18.7 million. Approximately $6.0 million was paid at closing with approximately $12.7 million payable over fiscal years 2015 through 2017. In fiscal 2015, 2014 and 2013, the Company paid cash for income taxes of $42.6 million, $55.2 million and $51.6 million, respectively. In fiscal 2016, stock options for 494 shares of common stock were exercised by the surrender of 306 shares of common stock at fair market value of $31,000. In fiscal 2015, stock options for 385 shares of common stock were exercised by the surrender of 309 shares of common stock at fair market value of $31,000. In fiscal 2014, stock options for 1,077 shares of common stock were exercised by the surrender of 733 shares of common stock at fair market value of $56,000.

Note 14 - Accumulated Other Com

Note 14 - Accumulated Other Comprehensive Income	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	Note 14. Accumulated Other Comprehensive Income: Changes in accumulated other comprehensive income (loss), net of tax, for the year ended June 30, 2016 consists of (in thousands): Unrealized Gains (Losses) on Available-for-Sale Investments Foreign Currency Translation Adjustments Total Beginning balance $ 14,382 (44,975 ) $ (30,593 ) Other comprehensive income (loss) (19,924 ) (19,932 ) (39,812 ) Ending balance $ (5,542 ) (64,907 ) (70,405 )

Note 15 - Subsequent Event

Note 15 - Subsequent Event	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	Note 15. Subsequent Events: On July 1, 2016 Bio-Techne acquired Space Import-Export Srl (Space) of Milan, Italy for approximately $11 million. Space is a long and trusted partner of Bio-Techne, distributing its products since 1985 and creating a very effective and visible presence in the Italian market. Space’s Mr. Luca Cicchetti, will remain with Bio-Techne as Managing Director and lead the Company’s southern European commercial operations. On August 1, 2016, Bio-Techne closed on the acquisition of Advanced Cell Diagnostics (ACD) for $250 million in cash plus contingent consideration of $75 million due upon the achievement of certain milestones. The transaction was financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne obtained prior to the closing of the acquisition. In connection with the acquisition of Advanced Cell Diagnostics on August 1, 2016, the Company entered into a new revolving credit facility, governed by a Credit Agreement dated July 28, 2016. The Credit Agreement provides for a revolving credit facility of $400 million. Borrowings under the Credit Agreement bear interest at a variable rate. As of August 26, 2016, the Company had drawn $250 million under the Credit Agreement.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Estimates:
Consolidation, Policy [Policy Text Block]	Principles of consolidation:
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Translation of foreign financial statements:
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition:
Research and Development Expense, Policy [Policy Text Block]	Research and development:
Advertising Costs, Policy [Policy Text Block]	Advertising costs:
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-based compensation:
Income Tax, Policy [Policy Text Block]	Income taxes: In November 2015, the FASB issued ASU 2015-17, "Income Taxes: Balance Sheet Classification of Deferred Taxes." ASU 2015-17 requires that deferred income tax liabilities and assets be classified as non-current in a statement of financial position. The Company elected early adoption of this guidance during the quarter ended March 31, 2016, on a prospective basis. The adoption of this ASU allows the Company to simplify its presentation of deferred income tax liabilities and assets. Prior periods were not retrospectively adjusted.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial instruments not measured at fair value:
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and equivalents:
Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block]	Available-for-sale investments: Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. Unrealized gains and losses on available-for-sale securities are excluded from income, but are included, net of taxes, in other comprehensive income. If an “other-than-temporary” impairment is determined to exist, the difference between the value of the investment security recorded in the financial statements and the Company’s current estimate of the fair value is recognized as a charge to earnings in the period in which the impairment is determined.
Inventory, Policy [Policy Text Block]	Inventories:
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment:
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill:
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible assets:
Equity Method Investments, Policy [Policy Text Block]	Investments in unconsolidated entities:

Note 2 - Acquisitions (Tables)

Note 2 - Acquisitions (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Zephyrus Cliniqa Novus Protein Simple CyVek Bionostics PrimeGene Current assets $ 86 $ 11,926 $ 10,739 $ 19,660 $ 1,206 $ 9,605 $ 1,272 Equipment 32 1,436 1,266 1,983 971 2,180 546 Other long-term assets 58 40 554 19 Intangible Assets: In process research and development 7,400 - - - - - - Developed technology - 18,000 5,010 39,200 20,200 14,400 2,200 Trade name - 1,100 5,300 36,100 100 2,700 3,000 Customer relationships - 27,000 14,400 101,600 600 41,000 9,100 Non-compete agreements - - - 200 - 2,400 322 Goodwill 6,878 42,669 28,408 134,074 91,658 56,349 5.518 Total assets acquired 14,396 102,189 65,163 333,371 114,754 128,634 21,958 Liabilities 54 1,508 2,166 11,644 1,965 3,007 887 Deferred income taxes, net 2,812 17,793 2,875 21,674 (438 ) 22,478 2,310 Net assets 11,530 82,888 $ 60,122 $ 300,053 $ 113,227 $ 103,149 $ 18,761 Less fair-value of previous investment - - - - 18,300 - - Net assets acquired 11,530 82,888 60,122 300,053 94,927 103,149 18,761 Cash paid, net of cash acquired $ 8,030 $ 82,888 $ 60,122 $ 300,053 $ 59,927 $ 103,149 $ 6,031 Note Payable 0 0 0 0 0 0 12,730 Contingent consideration payable 3,500 - - - 35,000 - - Net purchase price $ 11,530 $ 82,888 $ 60,122 $ 300,053 $ 94,927 $ 103,149 $ 18,761

Note 3 - Available-for-sale I25

Note 3 - Available-for-sale Investments (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Available-for-sale Securities [Table Text Block]	June 30, 201 6 201 5 Cost Market Cost Market Certificates of deposit $ 3,016 $ 3,017 $ 4,089 $ 4,089 Equity securities 29,472 28,581 29,472 52,300 $ 32,488 $ 31,598 $ 33,561 $ 56,389

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 201 6 201 5 Raw materials $ 22,963 $ 15,892 Finished goods 34,139 33,685 $ 57,102 $ 49,577

Note 5 - Property and Equipme27

Note 5 - Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, 201 6 201 5 Cost: Land $ 6,270 $ 7,370 Buildings and improvements 157,963 156,965 Machinery, equipment and other 82,018 74,385 246,251 238,720 Accumulated depreciation and amortization (113,889 ) (108,967 ) $ 132,362 $ 129,749

Note 6 - Intangibles Assets a28

Note 6 - Intangibles Assets and Goodwill (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	June 30, Useful Life (years) 201 6 201 5 Developed technology 8 - 15 $ 120,611 $ 108,887 Trade names 5 - 16 63,706 63,867 Customer relationships 8 - 16 191,118 167,494 Non-compete agreement 3 - 5 3,284 3,298 378,719 343,546 Accumulated amortization (75,595 ) (50,707 ) Total amortizeable intagibles $ 303,124 $ 292,839 In process research and development 7,400 0 Total intangible assets 310,524 292,839 Goodwill $ 430,882 $ 390,638
Schedule of Goodwill [Table Text Block]	Year Ended June 30, 201 6 201 5 Beginning balance $ 390,638 $ 151,473 Acquisitions 49,648 254,140 Currency translation (9,404 ) (14,975 ) Ending balance $ 430,882 $ 390,638
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Year Ended June 30, 201 6 201 5 Beginning balance $ 292,839 $ 108,776 Acquisitions 53,500 222,710 Amortization expense (29,395 ) (26,170 ) Currency translation (6,420 ) (12,777 ) Ending balance $ 310,524 $ 292,839
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ending June 30: 2017 28,326 2018 28,140 2019 27,527 2020 26,898 2021 26,534 Thereafter 165,699 $ 303,124

Note 8 - Commitments and Cont29

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Operating Leases of Lessee Disclosure [Table Text Block]	Year Ending June 30: 2017 6,326 2018 5,801 2019 4,810 2020 4,761 2021 4,815 Thereafter 19,120 $ 45,633

Note 9 - Share-based Compensa30

Note 9 - Share-based Compensation and Other Benefit Plans (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Shares Weighted Weighted Aggregate (millions) Outstanding at June 30, 2013 728 66.70 Granted 251 80.88 Forfeited (26 ) 76.23 Exercised (142 ) 59.07 Outstanding at June 30, 2014 811 72.11 Granted 600 93.98 Forfeited (133 ) 92.85 Exercised (141 ) 69.31 Outstanding at June 30, 2015 1,137 81.57 Granted 805 105.16 Forfeited (54 ) 99.68 Exercised (69 ) 69.82 Outstanding at June 30, 2016 1,819 $ 91.91 5.3 $ 37.9 Exercisable at June 30: 2014 534 $ 69.49 2015 547 72.72 2016 596 75.74 4.2 $ 22.1
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended June 30, 201 6 201 5 201 4 Dividend yield 1.2% 1.3% 1.5% Expected volatility 20% - 23% 18% - 21% 18% - 22% Risk-free interest rates 1.2% - 1.9% 1.3% - 2.2% 1.4% - 2.1% Expected lives (years) 5 5 6

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended June 30, 201 6 201 5 201 4 Earnings before income taxes consist of: Domestic $ 120,154 $ 121,765 $ 127,681 Foreign 27,327 32,397 33,711 $ 147,481 $ 154,162 $ 161,392 Taxes on income consist of: Currently payable: Federal $ 34,805 $ 28,220 $ 40,967 State 2,958 6,165 1,709 Foreign 7,579 10,704 10,668 Net deferred: Federal 1,906 4,401 (1,137 ) State (428 ) 292 (41 ) Foreign (3,815 ) (3,355 ) (1,722 ) $ 43,005 $ 46,427 $ 50,444
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended June 30, 201 6 201 5 201 4 Computed expected federal income tax expense $ 51,618 $ 53,957 $ 56,487 State income taxes, net of federal benefit 1,852 4,762 1,048 Qualified production activity deduction (3,932 ) (3,140 ) (3,823 ) Non-taxable gain on investment 0 (2,905 ) 0 Research and development tax credit (1,550 ) (912 ) (476 ) Tax-exempt interest 0 0 (654 ) Foreign tax rate differences (4,639 ) (4,059 ) (2,857 ) Other (344 ) (1,276 ) 719 $ 43,005 $ 46,427 $ 50,444
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	June 30 201 6 201 5 Inventory $ 9,768 $ 8,753 Net operating loss carryovers 26,556 34,767 Tax credit carryovers 3,197 3,872 Excess tax basis in equity investments 4,544 4,496 Deferred compensation 5,912 3,747 Net unrealized loss on available for sale investment 329 0 Other 7,421 4,712 Valuation allowance (7,201 ) (2,558 ) Net deferred tax assets 50,526 57,789 Net unrealized gain on available-for-sale investments 0 (8,446 ) Intangible asset amortization (107,200 ) (96,401 ) Depreciation (5,132 ) (2,394 ) Other (1,031 ) (466 ) Deferred tax liabilities (113,363 ) (107,707 ) Net deferred tax liabilities $ (62,837 ) $ (49,918 )

Note 11 - Earnings Per Share (T

Note 11 - Earnings Per Share (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended June 30, 201 6 201 5 201 4 Net earnings used for basic and diluted earnings per share $ 104,476 $ 107,735 $ 110,948 Weighted average shares used in basic computation 37,194 37,096 36,890 Dilutive stock options 132 135 115 Weighted average shares used in diluted computation 37,326 37,231 37,005 Basic EPS $ 2.81 $ 2.90 $ 3.01 Diluted EPS $ 2.80 $ 2.89 $ 3.00

Note 12 - Segment Information (

Note 12 - Segment Information (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended June 30, 201 6 201 5 201 4 External sales Biotechnology $ 317,340 $ 308,437 $ 285,142 Clinical Controls 104,484 77,866 72,621 Protein Platforms 77,324 66,249 0 Inter segment (125 ) (306 ) 0 Consolidated net sales $ 499,023 $ 452,246 $ 357,763 Year Ended June 30, 201 6 201 5 201 4 Operating Income Biotechnology $ 168,613 $ 165,226 $ 162,621 Clinical Controls 30,412 23,981 22,976 Protein Platforms 3,592 4,469 0 Segment operating income 202,617 193,676 185,597 Costs recognized upon sale of acquired inventory (5,431 ) (6,952 ) (7,480 ) Amortization of intangibles (29,395 ) (26,169 ) (10,276 ) Stock based compensation (9,430 ) (5,957 ) (3,523 ) Acquisition related expenses (2,761 ) (4,519 ) (2,247 ) Corporate general, selling and administrative expenses (5,007 ) (3,056 ) (2,321 ) Consolidated operating income $ 150,593 $ 147,023 $ 159,750 Goodwill Biotechnology $ 105,380 $ 115,198 $ 90,872 Clinical Controls 106,692 60,601 60,601 Protein Platforms 218,810 214,839 0 Consolidated goodwill $ 430,882 $ 390,638 $ 151,473 Intangible assets, net Biotechnology $ 57,199 $ 68,777 $ 53,778 Clinical Controls 86,736 49,130 54,998 Protein Platforms 166,589 174,932 0 Consolidated intangible assets, net $ 310,524 $ 292,839 $ 108,776 Assets Biotechnology $ 387,470 $ 430,524 $ 674,854 Clinical Controls 212,649 74,954 66,072 Protein Platforms 440,343 444,899 0 Segment assets 1,040,462 950,378 740,917 Corporate cash and available- for- sale investments 31,255 52,800 60,142 Corporate property and equipment 56,195 58,270 60,350 Corporate, other 1,669 1,912 1,082 Consolidated assets $ 1,129,581 $ 1,063,360 $ 862,491 Depreciation and amortization Biotechnology $ 14,196 $ 13,820 $ 10,879 Clinical Controls 10,462 7,963 7,205 Protein Platforms 16,027 13,364 0 Segment depreciation and amortization 40,685 35,147 18,084 Corporate 2,079 2,079 1,091 Consolidated depreciation and amortization $ 42,764 $ 37,226 $ 19,175 Capital purchases Biotechnology $ 14,295 $ 9,794 $ 4,157 Clinical Controls 1,780 1,932 5,687 Protein Platforms 823 8,179 Segment capital purchases 16,898 19,905 9,844 Corporate 0 0 3,977 Consolidated capital purchases $ 16,898 $ 19,905 $ 13,821
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Year Ended June 30, 201 6 201 5 201 4 External sales United States $ 283,270 $ 245,217 $ 190,359 U.K. 88,680 68,055 55,144 Other Europe 51,047 66,022 42,013 China 27,205 26,105 18,878 Other Asia 24,809 23,806 32,704 Rest of world 24,012 23,041 18,665 Total external sales $ 499,023 $ 452,246 $ 357,763 Long-lived assets United States and Canada $ 118,027 $ 119,075 $ 109,790   Europe 14,423 11,239 8,340 China 1,109 1,286 678 Total long-lived assets $ 133,559 $ 131,600 $ 118,808

Note 14 - Accumulated Other C34

Note 14 - Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Unrealized Gains (Losses) on Available-for-Sale Investments Foreign Currency Translation Adjustments Total Beginning balance $ 14,382 (44,975 ) $ (30,593 ) Other comprehensive income (loss) (19,924 ) (19,932 ) (39,812 ) Ending balance $ (5,542 ) (64,907 ) (70,405 )

Note 1 - Description of Busin35

Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Building, Building Improvements and Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	5 years
Building, Building Improvements and Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	40 years
Goodwill, Impairment Loss	$ 0
Impairment of Intangible Assets (Excluding Goodwill)	0
Advertising Expense	$ 5,200,000	$ 4,100,000	$ 3,400,000
Available-for-Sale Securities, Debt Maturities, Date Range Low	90 days
Available-for-sale Securities, Debt Maturities, Date Range High	3 years
Goodwill	$ 430,882,000	$ 390,638,000	$ 151,473,000

Note 2 - Acquisitions (Details

Note 2 - Acquisitions (Details Textual)	Mar. 14, 2016USD ($)	Jul. 08, 2015USD ($)	Nov. 03, 2014USD ($)	Jul. 31, 2014USD ($)	Jul. 02, 2014USD ($)	Apr. 30, 2014USD ($)	Jul. 22, 2013USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2013USD ($)
Zephyrus [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 7,400,000
Zephyrus [Member] | Instruments Sales Contingency [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 3,500,000							$ 3,500,000
Business Combination, Contingent Consideration, Liability, Number of Instruments Sold	10
Business Combination, Contingent Consideration, Liability, Anniversary of Closing Date	3 years
Business Combination, Contingent Consideration, Liability, Cumulative Sales	$ 3,000,000
Business Combination, Contingent Consideration, Liability, Number of Years Within Closing Date	4 years 182 days
Zephyrus [Member]
Payments to Acquire Businesses, Gross	$ 8,000,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	7,000,000
Business Combination, Contingent Consideration, Liability	$ 3,500,000
Payments to Acquire Businesses, Net of Cash Acquired								8,030,000
Cliniqa [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 18,000,000
Finite-Lived Intangible Asset, Useful Life		14 years
Cliniqa [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 27,000,000
Finite-Lived Intangible Asset, Useful Life		13 years
Cliniqa [Member] | Trademarks and Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 1,100,000
Finite-Lived Intangible Asset, Useful Life		4 years
Cliniqa [Member]
Payments to Acquire Businesses, Net of Cash Acquired		$ 83,000,000						82,888,000
CyVek, Inc. [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 20,200,000
Finite-Lived Intangible Asset, Useful Life			15 years
CyVek, Inc. [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 100,000
Finite-Lived Intangible Asset, Useful Life			1 year 182 days
CyVek, Inc. [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 600,000
Finite-Lived Intangible Asset, Useful Life			10 years
CyVek, Inc. [Member] | Selling, General and Administrative Expenses [Member]
Business Combination, Acquisition Related Costs									$ 100,000
CyVek, Inc. [Member]
Payments to Acquire Businesses, Gross			$ 62,000,000						62,000,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High									35,000,000
Payments to Acquire Businesses, Net of Cash Acquired								59,927,000
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			$ 10,000,000
Noncontrolling Interest, Ownership Percentage by Parent			19.90%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability			$ 35,000,000
Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contingent Liability, Percentage			50.00%
Business Combination, Milestone Payment Threshold			$ 100,000,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized									35,000,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain			$ 8,300,000
ProteinSimple [Member] | Developed Technology Rights [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life				9 years
ProteinSimple [Member] | Developed Technology Rights [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life				10 years
ProteinSimple [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				$ 39,200,000
ProteinSimple [Member] | Trade Names [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life				18 years
ProteinSimple [Member] | Trade Names [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life				20 years
ProteinSimple [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				$ 36,100,000
ProteinSimple [Member] | Customer Relationships [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life				14 years
ProteinSimple [Member] | Customer Relationships [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life				16 years
ProteinSimple [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				$ 101,600,000
ProteinSimple [Member] | Noncompete Agreements [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				$ 200,000
Finite-Lived Intangible Asset, Useful Life				3 years
ProteinSimple [Member] | Selling, General and Administrative Expenses [Member]
Business Combination, Acquisition Related Costs								800,000
ProteinSimple [Member]
Payments to Acquire Businesses, Net of Cash Acquired								300,053,000
Novus Holdings, LLC [Member] | Developed Technology Rights [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life					4 years
Novus Holdings, LLC [Member] | Developed Technology Rights [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life					12 years
Novus Holdings, LLC [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					$ 5,000,000
Novus Holdings, LLC [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					$ 5,300,000
Finite-Lived Intangible Asset, Useful Life					20 years
Novus Holdings, LLC [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					$ 14,400,000
Finite-Lived Intangible Asset, Useful Life					15 years
Novus Holdings, LLC [Member]
Payments to Acquire Businesses, Net of Cash Acquired								60,122,000
Business Combination, Acquisition Related Costs					$ 100,000
PrimeGene [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						$ 2,200,000
Finite-Lived Intangible Asset, Useful Life						9 years
PrimeGene [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						$ 3,000,000
Finite-Lived Intangible Asset, Useful Life						11 years
PrimeGene [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						$ 9,100,000
Finite-Lived Intangible Asset, Useful Life						9 years
PrimeGene [Member] | Noncompete Agreements [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						$ 300,000
Finite-Lived Intangible Asset, Useful Life						3 years
PrimeGene [Member]
Payments to Acquire Businesses, Gross										$ 6,000,000
Payments to Acquire Businesses, Net of Cash Acquired						$ 6,000,000		6,031,000
Business Combination, Acquisition Related Costs						$ 400,000
Bionostics [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$ 14,400,000
Finite-Lived Intangible Asset, Useful Life							9 years
Bionostics [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$ 2,700,000
Finite-Lived Intangible Asset, Useful Life							5 years
Bionostics [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$ 41,000,000
Finite-Lived Intangible Asset, Useful Life							14 years
Bionostics [Member] | Noncompete Agreements [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$ 2,400,000
Finite-Lived Intangible Asset, Useful Life							3 years
Bionostics [Member] | Selling, General and Administrative Expenses [Member]
Business Combination, Acquisition Related Costs										500,000	$ 600,000
Bionostics [Member]
Payments to Acquire Businesses, Net of Cash Acquired								$ 103,149,000
Developed Technology Rights [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life								8 years
Developed Technology Rights [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life								15 years
Trade Names [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life								5 years
Trade Names [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life								16 years
Customer Relationships [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life								8 years
Customer Relationships [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life								16 years
Noncompete Agreements [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life								3 years
Noncompete Agreements [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life								5 years
Payments to Acquire Businesses, Net of Cash Acquired								$ 91,423,000	420,102,000	109,180,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain								$ 0	$ 8,300,000	$ 0

Note 2 - Acquisitions - Prelimi

Note 2 - Acquisitions - Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed Pending Final Valuation of Intangible Assets (Details) - USD ($)	Jul. 08, 2015	Apr. 30, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Zephyrus [Member] | In Process Research and Development [Member]
Intangible Assets:
Intangible assets			$ 7,400,000
Zephyrus [Member] | Developed Technology Rights [Member]
Intangible Assets:
Intangible assets
Zephyrus [Member] | Trade Names [Member]
Intangible Assets:
Intangible assets
Zephyrus [Member] | Customer Relationships [Member]
Intangible Assets:
Intangible assets
Zephyrus [Member] | Noncompete Agreements [Member]
Intangible Assets:
Intangible assets
Zephyrus [Member]
Current assets			86,000
Equipment			32,000
Other long-term assets
Intangible Assets:
Goodwill			6,878,000
Total assets acquired			14,396,000
Liabilities			54,000
Deferred income taxes, net			2,812,000
Net assets			11,530,000
Less fair-value of previous investment
Net assets acquired			11,530,000
Payments to Acquire Businesses, Net of Cash Acquired			8,030,000
Business Combination, Consideration Transferred, Liabilities Incurred			0
Contingent consideration payable			3,500,000
Business Combination, Consideration Transferred			11,530,000
Cliniqa [Member] | In Process Research and Development [Member]
Intangible Assets:
Intangible assets
Cliniqa [Member] | Developed Technology Rights [Member]
Intangible Assets:
Intangible assets			18,000,000
Cliniqa [Member] | Trade Names [Member]
Intangible Assets:
Intangible assets			1,100,000
Cliniqa [Member] | Customer Relationships [Member]
Intangible Assets:
Intangible assets			27,000,000
Cliniqa [Member] | Noncompete Agreements [Member]
Intangible Assets:
Intangible assets
Cliniqa [Member]
Current assets			11,926,000
Equipment			1,436,000
Other long-term assets			58,000
Intangible Assets:
Goodwill			42,669,000
Total assets acquired			102,189,000
Liabilities			1,508,000
Deferred income taxes, net			17,793,000
Net assets			82,888,000
Less fair-value of previous investment
Net assets acquired			82,888,000
Payments to Acquire Businesses, Net of Cash Acquired	$ 83,000,000		82,888,000
Business Combination, Consideration Transferred, Liabilities Incurred			0
Contingent consideration payable
Business Combination, Consideration Transferred			82,888,000
Novus Holdings, LLC [Member] | In Process Research and Development [Member]
Intangible Assets:
Intangible assets
Novus Holdings, LLC [Member] | Developed Technology Rights [Member]
Intangible Assets:
Intangible assets			5,010,000
Novus Holdings, LLC [Member] | Trade Names [Member]
Intangible Assets:
Intangible assets			5,300,000
Novus Holdings, LLC [Member] | Customer Relationships [Member]
Intangible Assets:
Intangible assets			14,400,000
Novus Holdings, LLC [Member] | Noncompete Agreements [Member]
Intangible Assets:
Intangible assets
Novus Holdings, LLC [Member]
Current assets			10,739,000
Equipment			1,266,000
Other long-term assets			40,000
Intangible Assets:
Goodwill			28,408,000
Total assets acquired			65,163,000
Liabilities			2,166,000
Deferred income taxes, net			2,875,000
Net assets			60,122,000
Less fair-value of previous investment
Net assets acquired			60,122,000
Payments to Acquire Businesses, Net of Cash Acquired			60,122,000
Business Combination, Consideration Transferred, Liabilities Incurred			0
Contingent consideration payable
Business Combination, Consideration Transferred			60,122,000	$ 60,000,000
ProteinSimple [Member] | In Process Research and Development [Member]
Intangible Assets:
Intangible assets
ProteinSimple [Member] | Developed Technology Rights [Member]
Intangible Assets:
Intangible assets			39,200,000
ProteinSimple [Member] | Trade Names [Member]
Intangible Assets:
Intangible assets			36,100,000
ProteinSimple [Member] | Customer Relationships [Member]
Intangible Assets:
Intangible assets			101,600,000
ProteinSimple [Member] | Noncompete Agreements [Member]
Intangible Assets:
Intangible assets			200,000
ProteinSimple [Member]
Current assets			19,660,000
Equipment			1,983,000
Other long-term assets			554,000
Intangible Assets:
Goodwill			134,074,000
Total assets acquired			333,371,000
Liabilities			11,644,000
Deferred income taxes, net			21,674,000
Net assets			300,053,000
Less fair-value of previous investment
Net assets acquired			300,053,000
Payments to Acquire Businesses, Net of Cash Acquired			300,053,000
Business Combination, Consideration Transferred, Liabilities Incurred			0
Contingent consideration payable
Business Combination, Consideration Transferred			300,053,000	300,000,000
CyVek, Inc. [Member] | In Process Research and Development [Member]
Intangible Assets:
Intangible assets
CyVek, Inc. [Member] | Developed Technology Rights [Member]
Intangible Assets:
Intangible assets			20,200,000
CyVek, Inc. [Member] | Trade Names [Member]
Intangible Assets:
Intangible assets			100,000
CyVek, Inc. [Member] | Customer Relationships [Member]
Intangible Assets:
Intangible assets			600,000
CyVek, Inc. [Member] | Noncompete Agreements [Member]
Intangible Assets:
Intangible assets
CyVek, Inc. [Member]
Current assets			1,206,000
Equipment			971,000
Other long-term assets			19,000
Intangible Assets:
Goodwill			91,658,000
Total assets acquired			114,754,000
Liabilities			1,965,000
Deferred income taxes, net			(438,000)
Net assets			113,227,000
Less fair-value of previous investment			18,300,000
Net assets acquired			94,927,000
Payments to Acquire Businesses, Net of Cash Acquired			59,927,000
Business Combination, Consideration Transferred, Liabilities Incurred			0
Contingent consideration payable			35,000,000
Business Combination, Consideration Transferred			94,927,000	95,000,000
Bionostics [Member] | In Process Research and Development [Member]
Intangible Assets:
Intangible assets
Bionostics [Member] | Developed Technology Rights [Member]
Intangible Assets:
Intangible assets			14,400,000
Bionostics [Member] | Trade Names [Member]
Intangible Assets:
Intangible assets			2,700,000
Bionostics [Member] | Customer Relationships [Member]
Intangible Assets:
Intangible assets			41,000,000
Bionostics [Member] | Noncompete Agreements [Member]
Intangible Assets:
Intangible assets			2,400,000
Bionostics [Member]
Current assets			9,605,000
Equipment			2,180,000
Other long-term assets
Intangible Assets:
Goodwill			56,349,000
Total assets acquired			128,634,000
Liabilities			3,007,000
Deferred income taxes, net			22,478,000
Net assets			103,149,000
Less fair-value of previous investment
Net assets acquired			103,149,000
Payments to Acquire Businesses, Net of Cash Acquired			103,149,000
Business Combination, Consideration Transferred, Liabilities Incurred			0
Contingent consideration payable
Business Combination, Consideration Transferred			103,149,000		$ 103,000,000
PrimeGene [Member] | In Process Research and Development [Member]
Intangible Assets:
Intangible assets
PrimeGene [Member] | Developed Technology Rights [Member]
Intangible Assets:
Intangible assets			2,200,000
PrimeGene [Member] | Trade Names [Member]
Intangible Assets:
Intangible assets			3,000,000
PrimeGene [Member] | Customer Relationships [Member]
Intangible Assets:
Intangible assets			9,100,000
PrimeGene [Member] | Noncompete Agreements [Member]
Intangible Assets:
Intangible assets			322,000
PrimeGene [Member]
Current assets			1,272,000
Equipment			546,000
Other long-term assets
Intangible Assets:
Goodwill			5,518
Total assets acquired			21,958,000
Liabilities			887,000
Deferred income taxes, net			2,310,000
Net assets			18,761,000
Less fair-value of previous investment
Net assets acquired			18,761,000
Payments to Acquire Businesses, Net of Cash Acquired		$ 6,000,000	6,031,000
Business Combination, Consideration Transferred, Liabilities Incurred			12,730,000		12,700,000
Contingent consideration payable
Business Combination, Consideration Transferred			18,761,000		18,700,000
Goodwill			430,882,000	390,638,000	151,473,000
Payments to Acquire Businesses, Net of Cash Acquired			91,423,000	420,102,000	$ 109,180,000
Contingent consideration payable			$ 38,500,000	$ 39,024,000

Note 3 - Available-for-sale I38

Note 3 - Available-for-sale Investments (Details Textual) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Chemo Centryx, Inc. [Member]
Available-for-sale Securities, Gross Unrealized Loss	$ 0.9
Available-for-sale, Amortized Cost Basis, Price Per Share	$ 4.73
Chemo Centryx, Inc. [Member]
Share Price	$ 4.49
Available-for-sale Securities, Gross Unrealized Gain, Accumulated InInvestments	$ 0.9	$ 22.8

Note 3 - Available-for-sale - A

Note 3 - Available-for-sale - Amortized Cost and Market Value of Available-for-sale Securities by Major Security Type (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Certificates Of Deposit [Member]
Cost	$ 3,016	$ 4,089
Market	3,017	4,089
Equity Securities [Member]
Cost	29,472	29,472
Market	28,581	52,300
Cost	32,488	33,561
Market	$ 31,598	$ 56,389

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($) $ in Millions	Jun. 30, 2016	Jun. 30, 2015
Proteins and Antibodies [Member]
Inventory Valuation Reserves	$ 23.4	$ 24

Note 4 - Inventories - Inventor

Note 4 - Inventories - Inventories (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Raw materials	$ 22,963,000	$ 15,892,000
Finished goods	34,139,000	33,685,000
	$ 57,102,000	$ 49,577,000

Note 5 - Property and Equipme42

Note 5 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Cost:
Land	$ 6,270	$ 7,370
Buildings and improvements	157,963	156,965
Machinery, equipment and other	82,018	74,385
	246,251	238,720
Accumulated depreciation and amortization	(113,889)	(108,967)
	$ 132,362	$ 129,749

Note 6 - Intangibles Assets a43

Note 6 - Intangibles Assets and Goodwill (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Developed Technology Rights [Member] | Cost of Sales [Member]
Amortization of Intangible Assets	$ 11.1	$ 9.5	$ 4.2
Trade Names, Customer Relationships, and Non-compete Agreement [Member] | Selling, General and Administrative Expense [Member]
Amortization of Intangible Assets	$ 18.3	$ 16.7	$ 6.1

Note 6 - Intangible Assets and

Note 6 - Intangible Assets and Goodwill - Intangible Assets (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Minimum [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life	8 years
Minimum [Member] | Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life	5 years
Minimum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life	8 years
Minimum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life	3 years
Maximum [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life	15 years
Maximum [Member] | Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life	16 years
Maximum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life	16 years
Maximum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life	5 years
Developed Technology Rights [Member]
Gross	$ 120,611,000	$ 108,887,000
Trade Names [Member]
Gross	63,706,000	63,867,000
Customer Relationships [Member]
Gross	191,118,000	167,494,000
Noncompete Agreements [Member]
Gross	3,284,000	3,298,000
In Process Research and Development [Member]
Gross	7,400,000	0
Gross	378,719,000	343,546,000
Accumulated amortization	(75,595,000)	(50,707,000)
Total amortizeable intagibles	303,124,000	292,839,000	$ 108,776,000
Total intangible assets	310,524,000	292,839,000
Goodwill	$ 430,882,000	$ 390,638,000	$ 151,473,000

Note 6 - Intangible Assets an45

Note 6 - Intangible Assets and Goodwill - Changes in Carrying Amount of Goodwill (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Beginning balance	$ 390,638,000	$ 151,473,000
Acquisitions	49,648,000	254,140,000
Currency translation	(9,404,000)	(14,975,000)
Ending balance	$ 430,882,000	$ 390,638,000

Note 6 - Intangible Assets an46

Note 6 - Intangible Assets and Goodwill - Changes in Carrying Amount of Intangible Assets (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Beginning balance	$ 292,839,000	$ 108,776,000
Acquisitions	53,500,000	222,710,000
Amortization expense	(29,395,000)	(26,170,000)
Currency translation	(6,420,000)	(12,777,000)
Ending balance	$ 303,124,000	$ 292,839,000

Note 6 - Intangible Assets an47

Note 6 - Intangible Assets and Goodwill - Estimated Future Amortization for Intangible Assets (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
2,017	$ 28,326,000
2,018	28,140,000
2,019	27,527,000
2,020	26,898,000
2,021	26,534,000
Thereafter	165,699,000
	$ 303,124,000	$ 292,839,000	$ 108,776,000

Note 7 - Debt and Other Finan48

Note 7 - Debt and Other Financing Arrangements (Details Textual) - USD ($) $ in Millions	Jul. 28, 2014	Mar. 31, 2016	Jul. 28, 2016	Jun. 30, 2016
Revolving Credit Facility [Member] | Federal Funds Effective Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	0.50%
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.00%
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Revolving Credit Facility [Member] | Subsequent Event [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 400
Revolving Credit Facility [Member]
Line of Credit Facility, Expiration Date		Jul. 31, 2019
Line of Credit Facility, Current Borrowing Capacity	$ 150
Line of Credit Facility, Additional Borrowing Capacity	$ 150
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.15%
Long-term Line of Credit				$ 91.5

Note 8 - Commitments and Cont49

Note 8 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Operating Leases, Rent Expense, Net	$ 8.1	$ 4.9	$ 1.6

Note 8 - Commitments and Cont50

Note 8 - Commitments and Contingencies - Aggregate Net Minimum Rental Commitments (Details) $ in Thousands	Jun. 30, 2016USD ($)
2,017	$ 6,326
2,018	5,801
2,019	4,810
2,020	4,761
2,021	4,815
Thereafter	19,120
	$ 45,633

Note 9 - Share-based Compensa51

Note 9 - Share-based Compensation and Other Benefit Plans (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Equity Incentive Plan 2010 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Equity Incentive Plan 2010 [Member] | Selling, General and Administrative Expenses [Member]
Stock or Unit Option Plan Expense	$ 9,400,000	$ 5,900,000	$ 3,500,000
Equity Incentive Plan 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,800,000
Nonqualified Stock Options Plan 1998 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	98,000
Incentive Stock Options Plan 1997 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	9,000
Employee Stock Purchase Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	200,000
Allocated Share-based Compensation Expense	$ 144,000
Performance Incentive Programs [Member] | Restricted Stock [Member] | Executive Officer [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	11,522		17,855
Performance Incentive Programs [Member] | Restricted Stock Units (RSUs) [Member] | Executive Officer [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	26,583		5,000
Performance Incentive Programs [Member] | Executive Officer [Member]
Officers' Compensation	$ 4,200,000	$ 1,900,000	$ 900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	621,000	322,000	216,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	19,994	9,000	26,355
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 91.78	$ 86.60
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	22,545	19,102	36,355
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	10,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	35,083	36,192	5,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 105.01		$ 94.13
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 15,900,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 73 days
Profit Sharing and Savings Plan [Member] | UNITED STATES
Pension and Other Postretirement Benefit Expense	$ 1,200,000	$ 1,100,000	$ 700,000
Profit Sharing and Savings Plan [Member] | UNITED KINGDOM
Pension and Other Postretirement Benefit Expense	$ 800,000	$ 700,000	$ 600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,819	1,137	811	728
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 18.50	$ 15.01	$ 14.77
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 2,400,000	$ 3,500,000	$ 3,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 1,600,000	$ 2,300,000	$ 2,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 99.53
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	805	600	251

Note 9 - Share-based Compensa52

Note 9 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Outstanding, shares (in shares)	1,137	811	728
Outstanding, weighted average exercise price (in dollars per share)	$ 81.57	$ 72.11	$ 66.70
Outstanding, aggregate intrinsic value
Granted, shares (in shares)	805	600	251
Granted, weighted average exercise price (in dollars per share)	$ 105.16	$ 93.98	$ 80.88
Forfeited, shares (in shares)	(54)	(133)	(26)
Forfeited, weighted average exercise price (in dollars per share)	$ 99.68	$ 92.85	$ 76.23
Exercised, shares (in shares)	(69)	(141)	(142)
Exercised, weighted average exercise price (in dollars per share)	$ 69.82	$ 69.31	$ 59.07
Outstanding, shares (in shares)	1,819	1,137	811
Outstanding, weighted average exercise price (in dollars per share)	$ 91.91	$ 81.57	$ 72.11
Outstanding, aggregate intrinsic value	$ 37.9
Outstanding, weighted average contractual life	5 years 109 days
Exercisable, shares (in shares)	596	547	534
Exercisable, weighted average exercise price (in dollars per share)	$ 75.74	$ 72.72	$ 69.49
Exercisable, shares (in shares)	596	547	534
Exercisable, weighted average exercise price (in dollars per share)	$ 75.74	$ 72.72	$ 69.49
Exercisable, shares (in shares)	596	547	534
Exercisable, weighted average exercise price (in dollars per share)	$ 75.74	$ 72.72	$ 69.49
Exercisable, weighted average contractual life	4 years 73 days
Exercisable, aggregate intrinsic value	$ 22.1

Note 9 - Share-based Compensa53

Note 9 - Share-based Compensation and Other Benefit Plan - Assumptions Used in Black-Scholes Option-Pricing Model (Details)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Minimum [Member]
Expected volatility	20.00%	18.00%	18.00%
Risk-free interest rates	1.20%	1.30%	1.40%
Maximum [Member]
Expected volatility	23.00%	21.00%	22.00%
Risk-free interest rates	1.90%	2.20%	2.10%
Dividend yield	1.20%	1.30%	1.50%
Expected volatility
Risk-free interest rates
Expected lives (years)	5 years	5 years	6 years

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) € in Millions	12 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015EUR (€)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)
R&D Europe [Member]
Cash Dividends Paid to Parent Company by Consolidated Subsidiaries | €		€ 46.6
Income Tax Expense (Benefit)			$ 1,700,000
Capital Loss Carryforward [Member]
Deferred Tax Assets, Valuation Allowance	$ 5,000,000		0
Operating Loss and Credit Carryforwards [Member]
Deferred Tax Assets, Valuation Allowance	2,000,000		2,400,000
Deferred Tax Assets, Investment [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	5,000,000
Deferred Tax Asset, Operating Loss Carry Forwards [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(300,000)
Operating Loss Carryforwards [Member]
Deferred Tax Assets, Net of Valuation Allowance	24,900,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	63,900,000
Tax Credit Carryforward, Amount	1,700,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	71,600,000
Tax Credit Carryforward, Amount	1,300,000
Foreign Tax Authority [Member]
Operating Loss Carryforwards	$ 2,100,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%
Change in Effective Income Tax Rate, Percentage	(0.90%)
Income Tax Expense (Benefit)	$ 43,005,000		46,427,000	$ 50,444,000
Deferred Tax Assets, Valuation Allowance	7,201,000		2,558,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	4,700,000
Deferred Tax Assets, Net of Valuation Allowance	50,526,000		57,789,000
Deferred Tax Assets, Tax Credit Carryforwards	3,197,000		$ 3,872,000
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries	$ 57,600,000

Note 10 - Income Taxes - Compon

Note 10 - Income Taxes - Components of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Earnings before income taxes consist of:
Domestic	$ 120,154	$ 121,765	$ 127,681
Foreign	27,327	32,397	33,711
	147,481	154,162	161,392
Currently payable:
Federal	34,805	28,220	40,967
State	2,958	6,165	1,709
Foreign	7,579	10,704	10,668
Net deferred:
Federal	1,906	4,401	(1,137)
State	(428)	292	(41)
Foreign	(3,815)	(3,355)	(1,722)
	$ 43,005	$ 46,427	$ 50,444

Note 10 - Income Taxes - Reconc

Note 10 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Computed expected federal income tax expense	$ 51,618,000	$ 53,957,000	$ 56,487,000
State income taxes, net of federal benefit	1,852,000	4,762,000	1,048,000
Qualified production activity deduction	(3,932,000)	(3,140,000)	(3,823,000)
Non-taxable gain on investment	0	(2,905,000)	0
Research and development tax credit	(1,550,000)	(912,000)	(476,000)
Tax-exempt interest	0	0	(654,000)
Foreign tax rate differences	(4,639,000)	(4,059,000)	(2,857,000)
Other	(344,000)	(1,276,000)	719,000
	$ 43,005,000	$ 46,427,000	$ 50,444,000

Note 10 - Income Taxes - Tempor

Note 10 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Inventory	$ 9,768,000	$ 8,753,000
Net operating loss carryovers	26,556,000	34,767,000
Tax credit carryovers	3,197,000	3,872,000
Excess tax basis in equity investments	4,544,000	4,496,000
Deferred compensation	5,912,000	3,747,000
Net unrealized loss on available for sale investment	329,000	0
Other	7,421,000	4,712,000
Valuation allowance	(7,201,000)	(2,558,000)
Net deferred tax assets	50,526,000	57,789,000
Net unrealized gain on available-for-sale investments	0	(8,446,000)
Intangible asset amortization	(107,200,000)	(96,401,000)
Depreciation	(5,132,000)	(2,394,000)
Other	1,031,000	466,000
Deferred tax liabilities	(113,363,000)	(107,707,000)
Net deferred tax liabilities	$ (62,837,000)	$ (49,918,000)

Note 11 - Earnings Per Share (D

Note 11 - Earnings Per Share (Details Textual) - shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,200,000	516,000	196,000

Note 11 - Earnings Per Share -

Note 11 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Net earnings used for basic and diluted earnings per share	$ 104,476,000	$ 107,735,000	$ 110,948,000
Basic (in shares)	37,194	37,096	36,890
Dilutive stock options (in shares)	132	135	115
Weighted average shares used in diluted computation (in shares)	37,326	37,231	37,005
Basic (in dollars per share)	$ 2.81	$ 2.90	$ 3.01
Diluted (in dollars per share)	$ 2.80	$ 2.89	$ 3

Note 12 - Segment Information60

Note 12 - Segment Information (Details Textual)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Clinical Controls [Member] | Sales Revenue, Segment [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Concentration Risk, Percentage		13.00%	14.00%
Number of Reportable Segments	3

Note 12 - Segment Information -

Note 12 - Segment Information - Financial Information Relating to Operating Segments (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Operating Segments [Member] | Biotechnology [Member]
External sales	$ 317,340,000	$ 308,437,000	$ 285,142,000
Operating Income	168,613,000	165,226,000	162,621,000
Consolidated operating income	168,613,000	165,226,000	162,621,000
Goodwill	105,380,000	115,198,000	90,872,000
Total amortizeable intagibles	57,199,000	68,777,000	53,778,000
Assets	387,470,000	430,524,000	674,854,000
Depreciation and amortization	14,196,000	13,820,000	10,879,000
Capital purchases	14,295,000	9,794,000	4,157,000
Operating Segments [Member] | Clinical Controls [Member]
External sales	104,484,000	77,866,000	72,621,000
Operating Income	30,412,000	23,981,000	22,976,000
Consolidated operating income	30,412,000	23,981,000	22,976,000
Goodwill	106,692,000	60,601,000	60,601,000
Total amortizeable intagibles	86,736,000	49,130,000	54,998,000
Assets	212,649,000	74,954,000	66,072,000
Depreciation and amortization	10,462,000	7,963,000	7,205,000
Capital purchases	1,780,000	1,932,000	5,687,000
Operating Segments [Member] | Protein Platforms [Member]
External sales	77,324,000	66,249,000	0
Operating Income	3,592,000	4,469,000	0
Consolidated operating income	3,592,000	4,469,000	0
Goodwill	218,810,000	214,839,000	0
Total amortizeable intagibles	166,589,000	174,932,000	0
Assets	440,343,000	444,899,000	0
Depreciation and amortization	16,027,000	13,364,000	0
Capital purchases	823,000	8,179,000
Operating Segments [Member]
Operating Income	202,617,000	193,676,000	185,597,000
Consolidated operating income	202,617,000	193,676,000	185,597,000
Assets	1,040,462,000	950,378,000	740,917,000
Depreciation and amortization	40,685,000	35,147,000	18,084,000
Capital purchases	16,898,000	19,905,000	9,844,000
Intersegment Eliminations [Member]
External sales	(125,000)	(306,000)	0
Segment Reconciling Items [Member]
Costs recognized upon sale of acquired inventory	(5,431,000)	(6,952,000)	(7,480,000)
Amortization of intangibles	(29,395,000)	(26,169,000)	(10,276,000)
Stock based compensation	(9,430,000)	(5,957,000)	(3,523,000)
Acquisition related expenses	(2,761,000)	(4,519,000)	(2,247,000)
Corporate, Non-Segment [Member]
Corporate general, selling and administrative expenses	(5,007,000)	(3,056,000)	(2,321,000)
Corporate cash and available- for- sale investments	31,255,000	52,800,000	60,142,000
Corporate property and equipment	56,195,000	58,270,000	60,350,000
Corporate, other	1,669,000	1,912,000	1,082,000
Depreciation and amortization	2,079,000	2,079,000	1,091,000
Capital purchases	0	0	3,977,000
External sales	499,023,000	452,246,000	357,763,000
Operating Income	150,593,000	147,023,000	159,750,000
Corporate general, selling and administrative expenses	140,879,000	119,401,000	60,716,000
Consolidated operating income	150,593,000	147,023,000	159,750,000
Goodwill	430,882,000	390,638,000	151,473,000
Total amortizeable intagibles	303,124,000	292,839,000	108,776,000
Assets	1,129,581,000	1,063,360,000	862,491,000
Corporate cash and available- for- sale investments	64,237,000	54,532,000	318,568,000	$ 163,786,000
Corporate property and equipment	132,362,000	129,749,000
Depreciation and amortization	42,764,000	37,226,000	19,175,000
Capital purchases	$ 16,898,000	$ 19,905,000	$ 13,821,000

Note 12 - Segment Information62

Note 12 - Segment Information - Financial Information Relating to Geographic Areas (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
UNITED STATES
External sales	$ 283,270,000	$ 245,217,000	$ 190,359,000
UNITED KINGDOM
External sales	88,680,000	68,055,000	55,144,000
Europe Other than U.K. [Member]
External sales	51,047,000	66,022,000	42,013,000
CHINA
External sales	27,205,000	26,105,000	18,878,000
Long-lived assets	1,109,000	1,286,000	678,000
Other Asia [Member]
External sales	24,809,000	23,806,000	32,704,000
Rest of World [Member]
External sales	24,012,000	23,041,000	18,665,000
United States and Canada [Member]
Long-lived assets	118,027,000	119,075,000	109,790,000
Europe [Member]
Long-lived assets	14,423,000	11,239,000	8,340,000
External sales	499,023,000	452,246,000	357,763,000
Long-lived assets	$ 133,559,000	$ 131,600,000	$ 118,808,000

Note 13 - Supplemental Disclo63

Note 13 - Supplemental Disclosures of Cash Flow Information and Noncash Investing and Financing Activities (Details Textual) - USD ($)	Mar. 14, 2016	Jul. 08, 2015	Nov. 03, 2014	Apr. 30, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Cliniqa [Member]
Business Combination, Consideration Transferred					$ 82,888,000
Payments to Acquire Businesses, Net of Cash Acquired		$ 83,000,000			82,888,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
Zephyrus [Member] | Instruments Sales Contingency [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 3,500,000				3,500,000
Zephyrus [Member]
Business Combination, Consideration Transferred					11,530,000
Payments to Acquire Businesses, Net of Cash Acquired					8,030,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	7,000,000
Payments to Acquire Businesses, Gross	$ 8,000,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
Novus Holdings, LLC [Member]
Business Combination, Consideration Transferred					60,122,000	$ 60,000,000
Payments to Acquire Businesses, Net of Cash Acquired					60,122,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
ProteinSimple [Member]
Business Combination, Consideration Transferred					300,053,000	300,000,000
Payments to Acquire Businesses, Net of Cash Acquired					300,053,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
CyVek, Inc. [Member]
Business Combination, Consideration Transferred					94,927,000	95,000,000
Payments to Acquire Businesses, Net of Cash Acquired					59,927,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						35,000,000
Payments to Acquire Businesses, Gross			$ 62,000,000			$ 62,000,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
Bionostics [Member]
Business Combination, Consideration Transferred					103,149,000		$ 103,000,000
Payments to Acquire Businesses, Net of Cash Acquired					103,149,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
PrimeGene [Member]
Business Combination, Consideration Transferred					18,761,000		18,700,000
Payments to Acquire Businesses, Net of Cash Acquired				$ 6,000,000	6,031,000
Payments to Acquire Businesses, Gross							6,000,000
Business Combination, Consideration Transferred, Liabilities Incurred					$ 12,730,000		12,700,000
Surrender of Common Stock [Member]
Conversion of Stock, Shares Issued					306	309
Payments to Acquire Businesses, Net of Cash Acquired					$ 91,423,000	$ 420,102,000	109,180,000
Income Taxes Paid, Net						$ 42,600,000	$ 55,200,000	$ 51,600,000
Conversion of Stock, Shares Issued					494	385	1,077
Conversion of Stock, Amount Converted					$ 31,000	$ 31,000	$ 56,000
Conversion of Stock, Shares Converted							733

Note 14 - Changes in Accumulate

Note 14 - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
Beginning balance	$ 14,382,000
Other comprehensive income (loss)	(19,924,000)
Ending balance	(5,542,000)	$ 14,382,000
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Beginning balance	(44,975,000)
Other comprehensive income (loss)	(19,932,000)
Ending balance	(64,907,000)	(44,975,000)
Beginning balance	(30,593,000)
Other comprehensive income (loss)	(39,812,000)	(25,205,000)	$ (19,941,000)
Ending balance	$ (70,405,000)	$ (30,593,000)

Note 15 - Subsequent Event (Det

Note 15 - Subsequent Event (Details Textual) - Subsequent Event [Member] - USD ($) $ in Millions	Aug. 01, 2016	Jul. 01, 2016	Aug. 26, 2016	Jul. 28, 2016
Space [Member]
Payments to Acquire Businesses, Gross		$ 11
Advanced Cell Diagnostics (ACD) [Member] | Upon the Achievement of Certain Milestones [Member]
Business Combination, Contingent Consideration, Liability	$ 75
Advanced Cell Diagnostics (ACD) [Member]
Payments to Acquire Businesses, Gross	$ 250
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 400
Proceeds from Lines of Credit			$ 250